These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 15535426

  • 1. G protein-coupled receptors as therapeutic targets for obesity and type 2 diabetes.
    Bjenning C, Al-Shamma H, Thomsen W, Leonard J, Behan D.
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1051-62. PubMed ID: 15535426
    [Abstract] [Full Text] [Related]

  • 2. Orphan G protein-coupled receptors and obesity.
    Xu YL, Jackson VR, Civelli O.
    Eur J Pharmacol; 2004 Oct 01; 500(1-3):243-53. PubMed ID: 15464037
    [Abstract] [Full Text] [Related]

  • 3. Alternative drug discovery approaches for orphan GPCRs.
    Levoye A, Jockers R.
    Drug Discov Today; 2008 Jan 01; 13(1-2):52-8. PubMed ID: 18190864
    [Abstract] [Full Text] [Related]

  • 4. G protein-coupled receptors as targets for anti-diabetic therapeutics.
    Oh DY, Olefsky JM.
    Nat Rev Drug Discov; 2016 Mar 01; 15(3):161-72. PubMed ID: 26822831
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological targeting of adipocytes/fat metabolism for treatment of obesity and diabetes.
    Pilch PF, Bergenhem N.
    Mol Pharmacol; 2006 Sep 01; 70(3):779-85. PubMed ID: 16760360
    [Abstract] [Full Text] [Related]

  • 6. GPR43: an emerging target for the potential treatment of type 2 diabetes, obesity and insulin resistance.
    Tiwari A.
    Curr Opin Investig Drugs; 2010 Apr 01; 11(4):385-93. PubMed ID: 20336586
    [Abstract] [Full Text] [Related]

  • 7. Endocrine receptors as targets for new drugs.
    Altman J.
    Neuroendocrinology; 2006 Apr 01; 83(5-6):282-8. PubMed ID: 16926529
    [Abstract] [Full Text] [Related]

  • 8. Deorphanisation of G protein-coupled receptors: A tool to provide new insights in nervous system pathophysiology and new targets for psycho-active drugs.
    Lecca D, Abbracchio MP.
    Neurochem Int; 2008 Feb 01; 52(3):339-51. PubMed ID: 17884255
    [Abstract] [Full Text] [Related]

  • 9. Interdependence of hepatic lipid and glucose metabolism: novel pharmacological targets for diabetes.
    Lind P.
    Curr Opin Investig Drugs; 2004 Apr 01; 5(4):395-401. PubMed ID: 15134280
    [Abstract] [Full Text] [Related]

  • 10. Regulation of AMP-activated protein kinase activity by G-protein coupled receptors: potential utility in treatment of diabetes and heart disease.
    Hutchinson DS, Summers RJ, Bengtsson T.
    Pharmacol Ther; 2008 Sep 01; 119(3):291-310. PubMed ID: 18606183
    [Abstract] [Full Text] [Related]

  • 11. The future of G protein-coupled receptors as targets in drug discovery.
    Lundstrom K.
    IDrugs; 2005 Nov 01; 8(11):909-13. PubMed ID: 16254784
    [Abstract] [Full Text] [Related]

  • 12. The endocannabinoid system: its roles in energy balance and potential as a target for obesity treatment.
    André A, Gonthier MP.
    Int J Biochem Cell Biol; 2010 Nov 01; 42(11):1788-801. PubMed ID: 20541029
    [Abstract] [Full Text] [Related]

  • 13. How well do rapid-acting insulins work in obese individuals?
    Barnett AH.
    Diabetes Obes Metab; 2006 Jul 01; 8(4):388-95. PubMed ID: 16776745
    [Abstract] [Full Text] [Related]

  • 14. [GPCRs heterodimerization: a new way towards the discovery of function for the orphan receptors?].
    Levoye A, Jockers R.
    Med Sci (Paris); 2007 Jul 01; 23(8-9):746-50. PubMed ID: 17875294
    [Abstract] [Full Text] [Related]

  • 15. [Molecular targets for new drug discovery to treat type 2 diabetes and obesity].
    Bastarrachea RA, Montero JC, Saavedra-Gajardo I, Cerda-Flores R, Machado-Domínguez A, Comuzzie AG.
    Rev Med Chil; 2008 Jan 01; 136(1):107-17. PubMed ID: 18483661
    [Abstract] [Full Text] [Related]

  • 16. Beta-cell function and mass in type 2 diabetes.
    Larsen MO.
    Dan Med Bull; 2009 Aug 01; 56(3):153-64. PubMed ID: 19728971
    [Abstract] [Full Text] [Related]

  • 17. Addressing the unmet medical need for safe and effective weight loss therapies.
    Arbeeny CM.
    Obes Res; 2004 Aug 01; 12(8):1191-6. PubMed ID: 15340099
    [Abstract] [Full Text] [Related]

  • 18. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec 01; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 19. Free fatty acid receptor family: novel targets for the treatment of diabetes and dyslipidemia.
    Bernard J.
    Curr Opin Investig Drugs; 2008 Oct 01; 9(10):1078-83. PubMed ID: 18821469
    [Abstract] [Full Text] [Related]

  • 20. Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines.
    Correia ML, Haynes WG.
    Expert Opin Emerg Drugs; 2005 Aug 01; 10(3):643-60. PubMed ID: 16083333
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.